D. Anderson Company Reports on 1st Quarter


Company News Release


, Texas

- D. Anderson  Company (DAC), an international patient recruitment and retention leader based in Dallas, posted a record first quarter on many fronts, including earnings, new business and requests for proposals. The privately held company, whose clientele is a who's who in pharmaceuticals and biotechnology, enters the second quarter brimming with optimism as contracts continue to outpace previous years.
Central to DAC's success is its growth in global markets and its ability to leverage 18 years of experience, including tenure as a Site Management Organization, niche Contract Research Organization and clinical trials recruitment provider.   
"In 2007 and 2008, the percent of DAC's business with international focus was 40 and 48 percent respectively for the entire year," said DAC President and CEO Diana Anderson, Ph.D. "Already, in 2009, half of new contracts are for global programs, with the remaining focused on North America. Large pharmaceutical companies represent 66 percent of new business so far this year."
Dr. Anderson has positioned DAC as an international player with experience in 62 countries and expertise in more than 40 therapeutic areas. The company has strong roots in rheumatology but, today, draws most of its business from the oncology, cardiovascular, central nervous system, and immunology sectors.   
DAC services include patient recruitment and retention, consulting, management, market research and customized training. With its full-service, in-house creative agency, DAC also combines messaging, design and branding to produce acclaimed marketing concepts.

About D. Anderson  Company

With offices in Seattle, Houston and Dallas, DAC is a subsidiary of D.L. Anderson International. The company is certified as a Women-Owned Business (WBE) by the Women's Business Enterprise National Council and a continuing education provider through the California Board of Registered Nursing. For more information, visit


Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.